Daiken Biomedical Co., Ltd. (TPE:7780)

Daiken Biomedical Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	246.95	106.58	160.35	90.17
Depreciation & Amortization	6	4.21	0.92	0.1
Provision & Write-off of Bad Debts	0.89	0.88	0	0
Other Operating Activities	28.07	-23.94	2.25	19.36
Change in Accounts Receivable	-57.23	-26.19	-14.65	-2.51
Change in Inventory	-44.71	16.95	-84.29	-121.33
Change in Accounts Payable	41.56	25.36	15.6	34.09
Change in Unearned Revenue	-2.7	-22.97	8.77	5.57
Change in Other Net Operating Assets	-4.17	-29.12	16.24	16.12
Operating Cash Flow	214.65	51.75	105.21	41.58
Operating Cash Flow Growth	458.60%	-50.81%	153.01%	-
Capital Expenditures	-0.2	-1.25	-	-
Sale (Purchase) of Intangibles	-5.37	-1.97	-	-0.05
Investment in Securities	219.64	92.12	-61.41	-
Other Investing Activities	-8.58	-4.8	-0.56	-31.9
Investing Cash Flow	205.5	84.09	-61.96	-31.95
Short-Term Debt Issued	-	470	183.83	33
Long-Term Debt Issued	-	-	65	127.36
Total Debt Issued	177	470	248.83	160.36
Short-Term Debt Repaid	-	-628	-58.83	-
Long-Term Debt Repaid	-	-121.24	-49.42	-24.36
Total Debt Repaid	-583.52	-749.24	-108.26	-24.36
Net Debt Issued (Repaid)	-406.52	-279.24	140.58	136
Issuance of Common Stock	-	1,000	-	-
Common Dividends Paid	-46.05	-3.08	-140.46	-
Financing Cash Flow	-452.58	717.68	0.12	136
Foreign Exchange Rate Adjustments	-7.52	-0.86	-	-
Net Cash Flow	-39.96	852.66	43.36	145.63
Free Cash Flow	214.45	50.5	105.21	41.58
Free Cash Flow Growth	473.77%	-52.00%	153.01%	-
Free Cash Flow Margin	13.18%	3.71%	8.84%	4.70%
Free Cash Flow Per Share	3.57	1.15	4.68	2.67
Cash Interest Paid	2.93	6	3.36	1.18
Cash Income Tax Paid	32.76	56.96	32.74	-
Levered Free Cash Flow	659.27	171.51	15.47	-
Unlevered Free Cash Flow	661.1	175.26	17.57	-
Change in Working Capital	-67.26	-35.99	-58.33	-68.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.